<DOC>
	<DOCNO>NCT00938223</DOCNO>
	<brief_summary>This open-label , phase II study vaccine comprise melanoma peptide tetanus helper peptide , administer GM-CSF-in-adjuvant . Patients randomize receive one two different vaccine regimen . Patients stratified stage disease ( IIB versus III versus IV ) .</brief_summary>
	<brief_title>Evaluation Immunogenicity Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor ( GM-CSF ) -In-Adjuvant , Patients With Advanced Melanoma</brief_title>
	<detailed_description>Each vaccination administer 6-week period ( day 1 , 8 , 15 , 29 , 36 , 43 ) . Patients randomize one two group , Group A Group B . Group A receive 4 class I MHC-restricted synthetic melanoma peptide ( 1 restrict HLA-A1 , -A3 , two restrict HLA-A2 ) tetanus helper peptide . Group B receive 12 class I MHC-restricted synthetic melanoma peptide ( 4 restrict HLA-A1 , -A2 , -A3 ) tetanus helper peptide . All vaccine contain GM-CSF-in-adjuvant administer intradermally subcutaneously . Concurrent first three vaccination , patient also receive additional set 3 identical vaccination distal site , response evaluate drain lymph node . This node harvest use lymphatic mapping sentinel node biopsy method refer sentinel immunize node ( SIN ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients diagnose , cytologic histologic examination , resect AJCC stage IIB , stage III , stage IV cutaneous mucosal melanoma . Patients brain metastasis eligible ( ) resect surgically , ( b ) 13 brain metastasis less equal 2 cm treat gammaknife stereotactic radiosurgery . Surgical resection gammaknife must complete great 10 month prior study entry . Tumor must express either gp100 ( patient HLAA2+ HLAA3+ ) tyrosinase ( patient HLAA1+ HLAA2+ ) immunohistochemistry . The tumor deposit ( ) examine primary lesion stage IIB patient , recently resect metastatic disease stage III stage IV patient . If recently resect deposit available material prior resect tumor evaluate . Patients refuse treatment IFNalpha despite candidate IFNalpha . Patients eligible treatment IFNalpha follow reason : active ischemic heart disease cerebrovascular disease , anginal syndrome require ongoing medication , history myocardial infarction , arrhythmia disorder , history treatment depression active depression , psychiatric disorder , patient autoimmune disorder exclude base criterion list section 5.2.8 present study , patient great 6 month elapse since definitive surgical therapy , hypersensitivity IFNalpha component associate treatment , debilitate medical condition severe pulmonary disease severe diabetes mellitus , patient thyroid abnormality whose thyroid function maintain normal range without medication patient resect stage IV disease provide meet eligibility criterion propose study , patient discontinue IFNalpha therapy due occurrence major toxicity document treat physician , patient undergo IFNalpha therapy experience tumor progression IFN complete IFN . All patient must : Karnofsky performance 80 % high , ECOG performance status 0 1 , Ability willingness give inform consent . Laboratory parameter follow : HLAA1 , A2 , A3 ( + ) , ANC &gt; 1000/mm3 , Platelets &gt; 100,000 Hgb &gt; 9 , Hepatic : AST ALT 2.5 x upper limit normal ( ULN ) , Bilirubin 2.5 x ULN , Alkaline phosphatase 2.5 x ULN , Renal : Creatinine 1.5 x ULN , Serology : HIV negative Hepatitis C negative within 6 month study entry , LDH 1.5 x ULN . Age 18 year old time study entry . Patients ocular melanoma . Patients currently receive cytotoxic chemotherapy , interferon , radiation receive therapy within precede 4 week . Patients currently receive nitrosoureas receive therapy within precede 6 week . Patients know suspected allergy component vaccine . Patients receive follow medication study entry within precede 4 week exclude : Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent ) , Allergy desensitization injection , Corticosteroids , administer parenterally orally . Topical corticosteroid acceptable . Any growth factor , Interleukin2 interleukins . Prior melanoma vaccination exclusion criterion . However , patient recur either administration melanoma vaccine eligible enroll 12 week follow last vaccination . Patients may vaccinate previously peptide include protocol . Other investigational drug investigational therapy necessarily exclusion criterion , similarly record take account data analysis . Pregnancy possibility become pregnant vaccine administration . Female patient childbearing potential must negative pregnancy test ( urinary serum betaHCG ) prior administration first vaccine dose . Males female must agree , consent form , use effective birth control method course vaccination . This consistent existing standard practice vaccine chemotherapy protocol . Patients medical contraindication potential problem complying requirement protocol , opinion investigator . Patients classify accord New York Heart Association classification Class III , IV heart disease . Patients systemic autoimmune disease visceral involvement . Patients another cancer diagnosis , except follow diagnosis allow : squamous cell cancer skin without know metastasis , basal cell cancer skin without know metastasis , carcinoma situ breast ( DCIS LCIS ) , carcinoma situ cervix , cancer without distant metastasis treat successfully , without evidence recurrence metastasis 5 year . Patients know addiction alcohol drug actively take agent , patient recent ( within 1 year ) ongoing illicit IV drug use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>peptide</keyword>
	<keyword>vaccine</keyword>
	<keyword>adjuvant</keyword>
	<keyword>advanced</keyword>
</DOC>